Clinical Trial

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

Study acronym: MITO 35B
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
MITO 35b is designed as randomized, open label, phase III trial that aims to assess the efficacy of olaparib maintenance beyond progression compered to standard platinum-based chemotherapy after secondary cytoreductive surgery. The target population of this study are ovarian cancer patients who experience a disease recurrence or progression to a first line maintenance therapy with PARPi; at progression patients must have received a secondary cytoreduction according to clinical practice.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-02-22; most recent amendment 2023-03-23.
Trial Details
NCT Number NCT05255471
Lead Sponsor National Cancer Institute, Naples
Conditions Ovarian Cancer
Enrollment 200 participants
Start Date 2022-01-21
Primary Completion 2028-01-21 (estimated)
Study Completion 2028-01-21 (estimated)
Updated on ClinicalTrials.gov 2023-03-24